Clinical trial NCT05874999: Acute Effects of Supramaximal High-Intensity Interval Training in People With COPD
Official title: Feasibility and Acute Effects of Supramaximal High-Intensity Interval Training in People With COPD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COPD
Healthy Older Adults
Keywords: Acute Exercise
High-intensity Interval Training
Lead sponsor: Umeå University
Sponsor class: OTHER
Collaborators: name: The Swedish Research Council
name: Swedish Heart Lung Foundation
name: Riksförbundet HjärtLung
First posted: 2023-05-25
Enrollment: 32
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: High-intensity exercise is essential for optimal development of cardiorespiratory fitness and health. This is, however, challenging for most people with chronic obstructive pulmonary disease (COPD) due to ventilatory limitations, leading to exercise at lower intensities accompanied by suboptimal stress on the cardiovascular and muscular system.

The aims of this cross-over trial is:

1. To compare the acute effects of short-duration supramaximal high-intensity interval training (HIIT) vs. traditional moderate-intensity continuous training (MICT) in people with COPD and matched healthy controls (HC).
2. To investigate the feasibility of supramaximal HIIT in people with COPD and matched HC.
3. To compare the cardiorespiratory demand, exercise intensity and symptoms during a modified Borg Cycle Strength Test (BCST) and a cardiopulmonary exercise test (CPET) in people with COPD and HC.

Detailed description: In this study, eligible participants attended the facility four times within 14 days with at least 48 hours of rest between visits.

Exercise tests (visit 1, week 1):

After pulmonary functions tests, a CPET on a stationary bicycle was performed according to international guidelines. After 1.5 hours of recovery, a BCST was performed to assess anaerobic exercise capacity and determine exercise intensities for supramaximal HIIT.

Exercise sessions (visit 2 - week 1; visit 3 - week 2; visit 4 - week 2):

The order of the two first exercise sessions (HIIT at 60% of MPO6 or MICT) on a stationary bicycle were randomized. The exercise session at HIIT at 80% of MPO6 was always the third exercise session.

During all exercise sessions, blood collection was performed at baseline after a 15-minute seated rest. During HIIT, blood was collected immediately after, and 30 minutes after the 10-minute HIIT period. For MICT, blood was collected after 10 minutes (isotime in relation to HIIT), immediately after, and 30 minutes of cycling at 60% MAP.

Eligibility criteria: COPD

Inclusion Criteria:

* COPD with non-reversible airflow obstruction diagnosis (post-bronchodilator forced expiratory volume during the first second/forced vital capacity (FEV1/FVC) \< 0.7)
* Age: \> 40 years

Exclusion Criteria:

* Recent exacerbation of COPD (\< 6 weeks)
* Neuromuscular, orthopaedic and/or any other condition that can compromise participation in testing
* Recent lung cancer (\< 5 years)
* Unstable cardiac disease and/or cardiac stimulator

HC

Inclusion Criteria:

- Age: \> 40 years

Exclusion Criteria:

* Neuromuscular, orthopaedic and/or any other condition that can compromise participation in testing
* Any respiratory disease
* Recent lung cancer (\< 5 years)
* Unstable cardiac disease and/or cardiac stimulator
* Too low or high physical activity level that prohibits matching

Primary outcomes:
measure: Exercise intensity
timeFrame: During visit 2 (week 1)
measure: Exercise intensity
timeFrame: During visit 3 (week 2)
measure: Exercise intensity
timeFrame: During visit 4 (week 2)
measure: Brain-derived neurotrophic factor (BDNF)
timeFrame: During visit 2 (week 1)
measure: Brain-derived neurotrophic factor (BDNF)
timeFrame: During visit 3 (week 2)
measure: Brain-derived neurotrophic factor (BDNF)
timeFrame: During visit 4 (week 2)
Secondary outcomes:
measure: Cardiorespiratory demand
timeFrame: During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
measure: Venous blood lactate concentration
timeFrame: During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
measure: Rating of perceived exertion
timeFrame: During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
measure: Rating of symptoms
timeFrame: During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
measure: Peripheral blood oxygen saturation (SpO2)
timeFrame: During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
measure: Blood pressure
timeFrame: During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
measure: Circulating levels of neurotrophic factors
timeFrame: During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
measure: Circulating levels of exerkines
timeFrame: During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
measure: Exercise session completion
timeFrame: During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
measure: Exercise preference
timeFrame: At the end of visit 3 (week 2)
measure: Session RPE
timeFrame: During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
measure: Exercise capacity
timeFrame: During visit 1 (CPET; week 1)
measure: Exercise intensity
timeFrame: During visit 1 (BCST; week 1)
measure: Adverse events
timeFrame: During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
Other outcomes:
Locations:
city: Umeå
country: Sweden
facility: Umeå University
Study officials:
affiliation: Umeå University
name: Andre Nyberg, PhD
role: PRINCIPAL_INVESTIGATOR
References: